U.S. Markets closed

Silverback Therapeutics, Inc. (SBTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.6600-0.0600 (-1.27%)
At close: 04:00PM EDT
4.6600 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.7200
Bid2.8100 x 1800
Ask4.9000 x 1000
Day's Range4.4500 - 4.7200
52 Week Range2.8000 - 11.8500
Avg. Volume303,738
Market Cap163.724M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.7690
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • American City Business Journals

    Silverback Therapeutics plans merger with San Diego biotech

    The move comes months after Seattle-based Silverback shuttered its oncology program. The combined company will focus on an epinephrine nasal spray called Neffy.

  • Benzinga

    Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment

    ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax

  • Business Wire

    Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

    SEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T